Home » Topics » Disease categories and therapies » Urology

Urology
RSS

New technology for BPH enters clinical trials in U.S.

Nov. 5, 1997

GelTex submits NDA for RenaGel

Nov. 4, 1997

Alza acquires rights to Ditropan

Oct. 24, 1997

Fujisawa describes bradykinin agonists with wide therapeutic application

Oct. 16, 1997

Oral desmopressin evaluated in bed-wetting children

Oct. 13, 1997

Vanguard licenses VML-252 to Sankyo

Oct. 10, 1997

TheraTech joins forces with Meiji and Sankyo to develop and market oxybutynin patch

Oct. 10, 1997

Unique profile described for Glaxo Wellcome's 5alpha-reductase inhibitor

Oct. 8, 1997

Empi's new incontinence device approved by FDA; worldwide launch slated for January

Oct. 7, 1997

Development of YM-46303 stopped

Oct. 2, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.